

**NOTICE OF NEW HAMPSHIRE MEDICAID
DRUG USE REVIEW BOARD
PUBLIC HEARING
October 25, 2010**

The New Hampshire Drug Use Review (DUR) Board invites you to attend a public hearing at 3:00 p.m., on October 25, 2010 at the Brown Building – Auditorium, 129 Pleasant Street, Concord, NH. A DUR meeting will immediately follow this public hearing.

The purpose of the public hearing on October 25, 2010, is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid preferred drug list and pharmacy prior authorization criteria.

The public hearing will begin at 3:00 p.m. and end no later than 4:00 p.m. The DUR meeting will begin at or before 4:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the preferred drug list and prior authorization criteria for the October 25, 2010 public hearing. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the preferred drug list and prior authorization criteria.

Written material may also be submitted by the public for DUR Board consideration if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

**DRUG USE REVIEW BOARD MEETING
October 25, 2010
Meeting Agenda**

I. Old Business

- a. Minutes – 6/22/10 review

II. New Business

1. Overview of Drug Utilization Patterns for New Hampshire Medicaid

- Prospective DUR Reports
- Utilization Reports
- Retrospective DUR Reports
- Update of Antipsychotic Utilization Review

2. Review of Current Preferred Drug List Therapeutic Classes with No Proposed Changes
Cardiovascular

- ACE Inhibitors & Combinations
- Angiotensin II Receptor Blockers & Combinations
- Beta-Blockers & Combinations
- Calcium Channel Blockers (DHP) & Combinations
- Calcium Channel Blockers (NON-DHP) & Combinations
- High Potency Statins & Combinations
- Statins & Combinations
- Cholesterol Absorption Inhibitors and Combinations
- Niacin Derivatives
- Triglyceride Lowering Agents
- Platelet Inhibitors
- Oral Pulmonary Hypertension Agents

Hematologic

- Hematopoietic Agents
- Low Molecular Weights Heparin

Topical

- Agents for Psoriasis
- Combination Benzoyl Peroxide & Clindamycin Products
- Immunomodulator
- Retinoids
- Antivirals
- Antibiotics

Behavioral Health

- Antihyperkinesia

Anticonvulsants

- Carbamazepine Derivatives
- First Generation
- Second Generation

3. Review of Current Clinical Prior Authorization Criteria with Proposed Changes
 - Brand Name Multiple Source Prescription Drug Product Criteria
 - CNS Stimulant Medications Criteria
 - Hematopoietic Agents Criteria
 - Symlin® Criteria
 - Transmucosal Analgesic Criteria
4. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes
 - Oral Isotretinoin Criteria
 - Topical Immunomodulator Criteria
 - Combination Benzoyl Peroxide & Clindamycin Criteria
5. Review of Proposed Clinical Prior Authorization Criteria
 - Multiple Sclerosis Medications
 - Huntington's Disease Medications

III. Adjourn

Further information regarding the agenda items may be obtained after October 11, 2010, by contacting Robin Calley, at 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: rlcalley@dhhs.state.nh.us.

Notice of intent to testify at the October 25, 2010 public hearing, and/or submittal of written comments, should be directed to Robin Calley, Office of Medicaid Business and Policy, 129 Pleasant Street, Concord, NH, 03301, 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: rlcalley@dhhs.state.nh.us.